While in March of this year the Journal of Pediatrics discovered a significant rate of heart inflammation and abnormalities as adverse effects of Pfizer COVID vaccines to adolescents, on June 3, the US Food and Drug Administration (FDA) has also recognized the risk of the same reactions from another brand Novavax, urging the company to highlight the data.
Therefore according to the FDA personnel, the agency already asked the company to flag the risk of myocarditis and pericarditis, an inflammation of the heart tissue. Myocarditis and pericarditis were also found in the data from the mRNA vaccine administration. And based on Novavax’s own documentation, FDA said experts should look into it further. The data from this company, according to their own statement, “was acquired before the Omicron and Delta variants spread across the world”.
Just recently, even the Australian government also sounded the alarm about cardiac inflammation or heart problem resulting from mRNA COVID vaccines. The Australian government announced last April of this year that risks to heart problems do exist, yet the problem is that governments still carry big pharma’s official narrative claiming this event is “rare” while downplaying the seriousness of the situation by talking only about those who recovered from the effects of the jab and not the ones who experienced severe health consequence. Posted on their website, here is what the Australian government wrote:
“Rarely, cases of myocarditis and pericarditis have been reported after the second dose of mRNA vaccine. It is particularly seen in males under 30 years old. Most cases are mild and patients have recovered quickly.”
And then it continued:
“New evidence suggests Vaxzevria (AstraZeneca) may also be associated with a small increased risk of myocarditis and pericarditis. The risk after AstraZeneca looks lower than the risk after Moderna or Pfizer. The risk of myocarditis and pericarditis after Nuvaxovid (Novavax) is not yet known. A small number of cases were reported in the trial for Novavax but we do not yet know if these were caused by the vaccine.”
Meanwhile, talking about the latest discovery from the Novavax document, the FDA stated on Friday:
“These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID19 vaccines…
Data from passive surveillance during post-authorization use in other countries also indicate a higher than expected rate of myocarditis and pericarditis (mainly pericarditis) associated with the vaccine. However, interpretation of these passive surveillance data is not straightforward, and further evaluation is needed to inform the risk of myocarditis and pericarditis associated with this vaccine, and their outcomes, as additional data emerge over time.”
The development of Novavax is, of course, another goal of the Bill and Melinda Gates Foundation (BMGF) and GAVI, the vaccine alliance. And through these powerful vaccine empires, holding the World Health Organization (WHO) in the neck, it was easily authorized in different countries around the world, especially in Europe. Unlike other notorious brands, Moderna, J&J, AstraZeneca, or Pfizer, Novavax developed a protein-based vaccine instead of an mRNA-based vaccine. But it’s interesting that even though its vaccine is not mRNA-based, it still causes myocarditis like some of those brands mentioned.
According to the statement about Novavax on the BMGF’s website:
“Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome…”
In the US and Mexico, there were 30,000 adult participants in Novavax’s study. And based on the report of the company’s administration, FDA was alarmed to find the risk of this heart problem. However, it is important to notice that even the mRNA-based vaccine should also be flagged and temporarily stopped by courts to be carefully and honestly studied for different risks. Because as the JAMA concluded:
“Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination.”
References:
https://www.wsj.com/market-data/quotes/NVAX/company-people
https://www.gatesfoundation.org/about/committed-grants/2020/07/inv021500
https://jamanetwork.com/journals/jama/fullarticle/2788346
https://medicalxpress.com/news/2022-06-fda-potential-novavax-myocarditis.html
